{"id":5157,"date":"2018-04-26T08:00:53","date_gmt":"2018-04-26T06:00:53","guid":{"rendered":"https:\/\/asscat-hepatitis.org\/una-formacion-dirigida-al-paciente-da-como-resultado-una-mejor-rvs-a-la-terapia-antiviral-en-un-gran-numero-de-pacientes-con-hepatitis-c-cronica-en-comparacion-con-la-informacion-convencional\/"},"modified":"2018-07-08T18:17:41","modified_gmt":"2018-07-08T16:17:41","slug":"una-formacion-dirigida-al-paciente-da-como-resultado-una-mejor-rvs-a-la-terapia-antiviral-en-un-gran-numero-de-pacientes-con-hepatitis-c-cronica-en-comparacion-con-la-informacion-convencional","status":"publish","type":"post","link":"https:\/\/asscat-hepatitis.org\/ca\/una-formacion-dirigida-al-paciente-da-como-resultado-una-mejor-rvs-a-la-terapia-antiviral-en-un-gran-numero-de-pacientes-con-hepatitis-c-cronica-en-comparacion-con-la-informacion-convencional\/","title":{"rendered":"Una formaci\u00f3 dirigida al pacient d\u00f3na com a resultat una millor RVS a la ter\u00e0pia antiviral en un gran nombre de pacients amb hepatitis C cr\u00f2nica en comparaci\u00f3 de la informaci\u00f3 convencional"},"content":{"rendered":"<p>[et_pb_section bb_built=&#8221;1&#8243; disabled_on=&#8221;off|off|off&#8221; _builder_version=&#8221;3.0.106&#8243; custom_margin=&#8221;|||&#8221; custom_padding=&#8221;0px||0px|&#8221; next_background_color=&#8221;#000000&#8243;][et_pb_row custom_padding=&#8221;0px||0px|&#8221; _builder_version=&#8221;3.0.106&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221;][et_pb_column type=&#8221;4_4&#8243;][et_pb_post_title author=&#8221;off&#8221; date_format=&#8221;d\/m\/Y&#8221; comments=&#8221;off&#8221; featured_placement=&#8221;background&#8221; text_background=&#8221;on&#8221; text_bg_color=&#8221;#ffffff&#8221; module_class=&#8221;ac-post-title-section-0&#8243; _builder_version=&#8221;3.0.106&#8243; title_font=&#8221;Montserrat|600|||||||&#8221; title_text_color=&#8221;#2d2d2d&#8221; title_letter_spacing=&#8221;-1px&#8221; title_line_height=&#8221;1.2em&#8221; meta_font=&#8221;Open Sans||||||||&#8221; meta_text_color=&#8221;rgba(45,45,45,0.5)&#8221; text_orientation=&#8221;center&#8221; custom_margin=&#8221;|||&#8221; custom_padding=&#8221;|20px|20px|20px&#8221; title_text_align=&#8221;center&#8221; meta_font_size=&#8221;13px&#8221; meta_text_align=&#8221;center&#8221;]<\/p>\n<p>&nbsp;<\/p>\n<p>[\/et_pb_post_title][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section bb_built=&#8221;1&#8243; specialty=&#8221;on&#8221; _builder_version=&#8221;3.0.106&#8243; custom_padding=&#8221;0px|||&#8221; prev_background_color=&#8221;#000000&#8243; next_background_color=&#8221;#000000&#8243;][et_pb_column type=&#8221;2_3&#8243; specialty_columns=&#8221;2&#8243;][et_pb_row_inner admin_label=&#8221;Fila&#8221; _builder_version=&#8221;3.0.106&#8243;][et_pb_column_inner type=&#8221;4_4&#8243; saved_specialty_column_type=&#8221;2_3&#8243;][et_pb_text admin_label=&#8221;Contenido Entrada 1&#8243; ul_type=&#8221;square&#8221; module_class=&#8221;ac-posts-content&#8221; _builder_version=&#8221;3.0.106&#8243; text_orientation=&#8221;justified&#8221; background_layout=&#8221;light&#8221;]<\/p>\n<h3>Segons un estudi presentat al Congr\u00e9s Internacional del Fetge de Par\u00eds, una formaci\u00f3 espec\u00edfica del pacient podria aportar beneficis al tractament de l&#8217;hepatitis C cr\u00f2nica i millorar la resposta a la ter\u00e0pia antiviral.<\/h3>\n<h3>Introducci\u00f3<\/h3>\n<p>Una formaci\u00f3 espec\u00edfica del pacient podria aportar beneficis al tractament de l&#8217;hepatitis C cr\u00f2nica i millorar la resposta a la ter\u00e0pia antiviral.<\/p>\n<p>Aquest estudi va tenir com a objectiu avaluar l&#8217;impacte del programa en l&#8217;efectivitat del tractament i els factors associats a la participaci\u00f3 en el programa d&#8217;educaci\u00f3, amb consultes dirigides per infermeres per al tractament de l&#8217;hepatitis C cr\u00f2nica.<\/p>\n<h3>Pacients i m\u00e8todes<\/h3>\n<p>Entre abril de 2014 i desembre de 2016 es van atendre de manera consecutiva 453 pacients que van rebre tractament amb antivirals d&#8217;acci\u00f3 directa (AADs). D&#8217;aquests, 30 van ser tractats amb interfer\u00f3 pegilat, ribavirina i Sofosbuvir, i 423 amb AADs + ribavirina. Tots els pacients van tenir l&#8217;oportunitat de participar en un programa d&#8217;educaci\u00f3 espec\u00edfic per al pacient.<\/p>\n<p>Es van comparar 23 variables, relatives al perfil del pacient, les caracter\u00edstiques de l&#8217;hepatitis C cr\u00f2nica, les modalitats de tractament i els f\u00e0rmacs associats entre els pacients que van participar i van ser adherents (PA +) o no (PA-) al programa. Es va realitzar una an\u00e0lisi multivariant segons un model de regressi\u00f3 log\u00edstica a partir de les variables significatives en l&#8217;an\u00e0lisi univariada.<\/p>\n<p>A m\u00e9s, les taxes de RVS12 es van comparar entre els pacients PA + i PA- d&#8217;acord amb el r\u00e8gim de tractament ia m\u00e9s entre els pacients PA +, d&#8217;acord amb el seu perfil (situaci\u00f3 prec\u00e0ria, migrants, usuaris de drogues).<\/p>\n<h3>Resultats<\/h3>\n<ul>\n<li>Van participar en el programa d&#8217;educaci\u00f3 al pacient 312 persones (69%).<\/li>\n<li>El nombre de les consultes realitzades a les infermeres va variar entre una-sis per pacient.<\/li>\n<li>Per a tots els tractaments realitzats en conjunt, la RVS12 va ser m\u00e9s gran entre els pacients que van participar en l&#8217;educaci\u00f3 del pacient (94,2%) en comparaci\u00f3 amb els que no van participar (89,3%) tot i que aquesta difer\u00e8ncia no va ser estad\u00edsticament significativa (p = 0,06).<\/li>\n<li>Aquesta superioritat tamb\u00e9 es va observar en els pacients tractats amb AAD + ribavirina (94,7% enfront de 88,6%; p = 0,009).<\/li>\n<li>En els pacients que van participar en l&#8217;educaci\u00f3 del pacient, la RVS ser independent de la situaci\u00f3 prec\u00e0ria, de l&#8217;estat migratori i de l&#8217;\u00fas de drogues, sent al voltant del 95%.<\/li>\n<\/ul>\n<h3>Conclusions<\/h3>\n<ul>\n<li><b>La majoria de pacients que van rebre tractament per hepatitis C cr\u00f2nica, van acceptar participar en un programa d&#8217;educaci\u00f3 espec\u00edfic per a pacients. D&#8217;aquesta manera, en els casos tractats amb AADs es va aconseguir millorar la seva RVS12.<\/b><\/li>\n<\/ul>\n<ul>\n<li><b>En poblacions vulnerables, gr\u00e0cies al programa d&#8217;educaci\u00f3 es van aconseguir resultats de RVS12 excel\u00b7lents i comparables amb els estudis de registre que van permetre l&#8217;autoritzaci\u00f3 dels nous f\u00e0rmacs AAD.<\/b><\/li>\n<\/ul>\n<h3>Comentari de l&#8217;ASSCAT<\/h3>\n<p>La informaci\u00f3 i educaci\u00f3 del pacient i la possibilitat de fer preguntes i exposar dubtes \u00e9s crucial i sempre defensem que el pacient ben informat \u00e9s un pacient adherent a les ter\u00e0pies i als controls.<\/p>\n<p>&nbsp;<\/p>\n<h6>Autors: Doffo\u00ebl M, y equipo (Servicio de expertos para la lucha contra la hepatitis viral de Alsacia, Hospital Universitario de Estrasburgo; Unidad de Psiquiatr\u00eda de Salud Mental, Hospital Universitario de Estrasburgo; SOS Hepatitis Alsacia; Labex HepSys, INSERM U1110, Estrasburgo).<\/h6>\n<h6>P\u00f3ster tradu\u00eft per l&#8217;ASSCAT (ILC 2018)<\/h6>\n<p>[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner admin_label=&#8221;Fila&#8221; custom_padding=&#8221;0px|||&#8221; _builder_version=&#8221;3.0.105&#8243; custom_margin=&#8221;|||&#8221;][et_pb_column_inner type=&#8221;4_4&#8243; saved_specialty_column_type=&#8221;2_3&#8243;][et_pb_post_title admin_label=&#8221;Metadatos &#8211; Fecha \u00daltima actualizaci\u00f3n&#8221; title=&#8221;off&#8221; author=&#8221;off&#8221; date_format=&#8221;d\/m\/Y&#8221; categories=&#8221;off&#8221; comments=&#8221;off&#8221; featured_image=&#8221;off&#8221; _builder_version=&#8221;3.0.106&#8243; title_text_align=&#8221;left&#8221; meta_font=&#8221;Open Sans||||||||&#8221; meta_text_align=&#8221;left&#8221; meta_font_size=&#8221;13px&#8221; meta_text_color=&#8221;#0082ca&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#cccccc&#8221; custom_margin=&#8221;50px|||&#8221; custom_padding=&#8221;10px|||&#8221; custom_css_before=&#8221;content:%22\u00daltima actualizaci\u00f3n:%22;&#8221; global_module=&#8221;3449&#8243; saved_tabs=&#8221;all&#8221;]<\/p>\n<p>&nbsp;<\/p>\n<p>[\/et_pb_post_title][\/et_pb_column_inner][\/et_pb_row_inner][\/et_pb_column][et_pb_column type=&#8221;1_3&#8243;][et_pb_sidebar orientation=&#8221;right&#8221; area=&#8221;et_pb_widget_area_8&#8243; module_class=&#8221;ac-posts-sidebar&#8221; _builder_version=&#8221;3.0.106&#8243; global_module=&#8221;3198&#8243; saved_tabs=&#8221;all&#8221;]<\/p>\n<p>&nbsp;<\/p>\n<p>[\/et_pb_sidebar][\/et_pb_column][\/et_pb_section][et_pb_section bb_built=&#8221;1&#8243; _builder_version=&#8221;3.0.106&#8243; custom_padding=&#8221;||0px|&#8221; prev_background_color=&#8221;#000000&#8243; module_class=&#8221;ac-post-section-share-rrss&#8221;][et_pb_row custom_padding=&#8221;||0px|&#8221; custom_margin=&#8221;|||&#8221; _builder_version=&#8221;3.0.105&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221;][et_pb_column type=&#8221;4_4&#8243;][et_pb_text _builder_version=&#8221;3.0.106&#8243; text_font=&#8221;Montserrat||||||||&#8221; text_text_color=&#8221;#e20611&#8243; text_orientation=&#8221;center&#8221; custom_margin=&#8221;||0px|&#8221; custom_padding=&#8221;|||&#8221; background_layout=&#8221;light&#8221;]<\/p>\n<h5>Des d&#8217;aqu\u00ed pots compartir aquesta publicaci\u00f3. Gr\u00e0cies!<\/h5>\n<p>[\/et_pb_text][et_pb_divider color=&#8221;#e20611&#8243; show_divider=&#8221;on&#8221; divider_style=&#8221;ridge&#8221; _builder_version=&#8221;3.0.106&#8243; \/][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n<!-- Begin Yuzo --><div class='yuzo_related_post style-1'  data-version='5.12.77'><!-- without result --><div class='yuzo_clearfixed yuzo__title yuzo__title'><h3>Related Post<\/h3><\/div>\n\t\t\t\t\t\t  <div class=\"relatedthumb \" style=\"width:125px;float:left;overflow:hidden;\">  \n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  <a  href=\"https:\/\/asscat-hepatitis.org\/ca\/tecentriq-de-roche-en-combinacio-amb-avastin-va-augmentar-la-supervivencia-global-i-la-supervivencia-lliure-de-progressio-en-persones-amb-carcinoma-hepatocel%c2%b7lular-no-ressecable\/\"  >\n\t\t\t\t\t\t\t\t\t  <div class=\"yuzo-img-wrap \" style=\"width: 125px;height:90px;\">\n\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t<div class=\"yuzo-img\" style=\"background:url('https:\/\/asscat-hepatitis.org\/wp-content\/uploads\/roche-150x150.jpeg') 50% 50% no-repeat;width: 125px;height:90px;margin-bottom: 5px;background-size: cover; \"><\/div>\n\t\t\t\t\t\t\t\t\t  <\/div>\n\t\t\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t\t   <span class=\"yuzo__text--title\" style=\"font-size:13px;\">Tecentriq de Roche en combinaci\u00f3 amb Avastin va au...<\/span>\n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  <\/a>\n\n\t\t\t\t\t\t  <\/div>\n\t\t\t\t\t\t  <div class=\"relatedthumb \" style=\"width:125px;float:left;overflow:hidden;\">  \n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  <a  href=\"https:\/\/asscat-hepatitis.org\/ca\/el-exito-clinico-del-plan-estrategico-para-el-abordaje-de-la-hepatitis-c\/\"  >\n\t\t\t\t\t\t\t\t\t  <div class=\"yuzo-img-wrap \" style=\"width: 125px;height:90px;\">\n\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t<div class=\"yuzo-img\" style=\"background:url('https:\/\/asscat-hepatitis.org\/wp-content\/uploads\/Casos-y-costes-evitados-en-varias-consecuencias-de-la-hepatitis-C-pre-y-post-Antivirales-Accio\u0301n-Directa-AAD-150x150.jpg') 50% 50% no-repeat;width: 125px;height:90px;margin-bottom: 5px;background-size: cover; \"><\/div>\n\t\t\t\t\t\t\t\t\t  <\/div>\n\t\t\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t\t   <span class=\"yuzo__text--title\" style=\"font-size:13px;\">L\u2019\u00e8xit (cl\u00ednic) del Pla Estrat\u00e8gic per a l&#...<\/span>\n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  <\/a>\n\n\t\t\t\t\t\t  <\/div>\n\t\t\t\t\t\t  <div class=\"relatedthumb \" style=\"width:125px;float:left;overflow:hidden;\">  \n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  <a  href=\"https:\/\/asscat-hepatitis.org\/ca\/aprovat-un-contracte-de-68-milions-per-a-la-compra-de-medicaments-oncologics-i-contra-lhepatitis-c-a-cantabria\/\"  >\n\t\t\t\t\t\t\t\t\t  <div class=\"yuzo-img-wrap \" style=\"width: 125px;height:90px;\">\n\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t<div class=\"yuzo-img\" style=\"background:url('https:\/\/asscat-hepatitis.org\/wp-content\/uploads\/servicio_cantabro_salud-150x150.jpg') 50% 50% no-repeat;width: 125px;height:90px;margin-bottom: 5px;background-size: cover; \"><\/div>\n\t\t\t\t\t\t\t\t\t  <\/div>\n\t\t\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t\t   <span class=\"yuzo__text--title\" style=\"font-size:13px;\">Aprovat un contracte de 6,8 milions per a la compr...<\/span>\n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  <\/a>\n\n\t\t\t\t\t\t  <\/div>\n\t\t\t\t\t\t  <div class=\"relatedthumb \" style=\"width:125px;float:left;overflow:hidden;\">  \n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  <a  href=\"https:\/\/asscat-hepatitis.org\/ca\/la-trombospondina-2-serica-es-un-nou-predictor-de-la-gravetat-en-els-pacients-amb-nafld\/\"  >\n\t\t\t\t\t\t\t\t\t  <div class=\"yuzo-img-wrap \" style=\"width: 125px;height:90px;\">\n\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t<div class=\"yuzo-img\" style=\"background:url('https:\/\/asscat-hepatitis.org\/wp-content\/uploads\/NAFLD-1-150x150.jpg') 50% 50% no-repeat;width: 125px;height:90px;margin-bottom: 5px;background-size: cover; \"><\/div>\n\t\t\t\t\t\t\t\t\t  <\/div>\n\t\t\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t\t   <span class=\"yuzo__text--title\" style=\"font-size:13px;\">La trombospondina 2 s\u00e8rica \u00e9s un nou predictor de ...<\/span>\n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  <\/a>\n\n\t\t\t\t\t\t  <\/div>\n<\/div> <style>\n\t\t\t\t\t\t\t\t.yuzo_related_post img{width:120px !important; height:110px !important;}\n\t\t\t\t\t\t\t\t.yuzo_related_post .relatedthumb{line-height:15px;background: !important;color:!important;}\n\t\t\t\t\t\t\t\t.yuzo_related_post .relatedthumb:hover{background:#fcfcf4 !important; -webkit-transition: background 0.2s linear; -moz-transition: background 0.2s linear; -o-transition: background 0.2s linear; transition: background 0.2s linear;;color:!important;}\n\t\t\t\t\t\t\t\t.yuzo_related_post .relatedthumb a{color:!important;}\n\t\t\t\t\t\t\t\t.yuzo_related_post .relatedthumb a:hover{ color:}!important;}\n\t\t\t\t\t\t\t\t.yuzo_related_post .relatedthumb:hover a{ color:!important;}\n\t\t\t\t\t\t\t\t.yuzo_related_post .yuzo_text {color:!important;}\n\t\t\t\t\t\t\t\t.yuzo_related_post .relatedthumb:hover .yuzo_text {color:!important;}\n\t\t\t\t\t\t\t\t.yuzo_related_post .relatedthumb{  margin: 0px  0px  0px  0px;   padding: 5px  5px  5px  5px;  }\n\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t<\/style> <script>\n\t\t\t\t\t\t  jQuery(document).ready(function( $ ){\n\t\t\t\t\t\t\t\/\/jQuery('.yuzo_related_post').equalizer({ overflow : 'relatedthumb' });\n\t\t\t\t\t\t\tjQuery('.yuzo_related_post .yuzo_wraps').equalizer({ columns : '> div' });\n\t\t\t\t\t\t   })\n\t\t\t\t\t\t  <\/script> <!-- End Yuzo :) -->","protected":false},"excerpt":{"rendered":"<p>Segons un estudi presentat al Congr\u00e9s Internacional del Fetge de Par\u00eds, una formaci\u00f3 espec\u00edfica del pacient podria aportar beneficis al tractament de l&#8217;hepatitis C cr\u00f2nica i millorar la resposta a la ter\u00e0pia antiviral.<\/p>\n","protected":false},"author":9,"featured_media":4186,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_crdt_document":"","footnotes":""},"categories":[491],"tags":[512,577,578,494,556,541],"class_list":["post-5157","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-noticias-de-prensa-ca","tag-antivirales-de-accion-directa-ca","tag-hepatitis-c-cronica-ca","tag-ilc-2018-ca","tag-prensa-ca","tag-respuesta-virologica-sostenida-ca","tag-terapia-antiviral-ca"],"_links":{"self":[{"href":"https:\/\/asscat-hepatitis.org\/ca\/wp-json\/wp\/v2\/posts\/5157","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/asscat-hepatitis.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/asscat-hepatitis.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/asscat-hepatitis.org\/ca\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/asscat-hepatitis.org\/ca\/wp-json\/wp\/v2\/comments?post=5157"}],"version-history":[{"count":0,"href":"https:\/\/asscat-hepatitis.org\/ca\/wp-json\/wp\/v2\/posts\/5157\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/asscat-hepatitis.org\/ca\/wp-json\/wp\/v2\/media\/4186"}],"wp:attachment":[{"href":"https:\/\/asscat-hepatitis.org\/ca\/wp-json\/wp\/v2\/media?parent=5157"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/asscat-hepatitis.org\/ca\/wp-json\/wp\/v2\/categories?post=5157"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/asscat-hepatitis.org\/ca\/wp-json\/wp\/v2\/tags?post=5157"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}